文献速递MDS 与骨髓增殖性肿瘤白血病

Cox比例风险深度神经网络识别外周血完全缓解在预测阿扎胞苷治疗患者结局方面至少等同于形态学完全缓解:AGMT前瞻性队列研究

Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
PubMed 文献 · Am J Hematol · 2023-08-07

该前瞻性队列研究纳入奥地利髓系登记处1441例非选择性连续患者(MDS 522例、CMML 132例、AML 787例),定义并验证了无需骨髓评估的外周血完全缓解(PB-CR)。校正17个协变量后,达到PB-CR者中位总生存为22.8个月(95%CI 18.9-26.2),未达到者为10.4个月(95%CI 9.7-11.2),HR=0.366(95%CI 0.303-0.441;p<.0001)。在达到形态学CR的患者中,额外达到PB-CR者中位校正OS为32.6个月(95%CI 26.2-49.2),未达到者为21.7个月(95%CI 16.9-27.7;HR=0.400,95%CI 0.190-0.844;p=.0161)。

要点

  • 在MDS、CMML和AML患者中,PB-CR可由血常规和临床参数判定,无需骨髓评估。
  • 达到PB-CR者中位校正OS为22.8个月,未达到者为10.4个月,HR=0.366。
  • 在形态学CR患者中,额外达到PB-CR者中位校正OS为32.6个月,未达到者为21.7个月,HR=0.400。

核心结论

  • 基于大型前瞻性队列的深度神经网络分析表明,仅以识别CR/CRi为目的的骨髓评估可以省略。

研究设计与样本

  • 前瞻性队列研究,纳入奥地利髓系登记处(aMYELOIDr;NCT04438889)1441例非选择性连续患者,其中MDS 522例(36.2%)、CMML 132例(9.2%)、AML 787例(54.6%)。
  • 采用Cox比例风险模型校正17个协变量,并使用DeepSurv(CPH神经网络模型)和基于置换的特征重要性验证结果。

主要发现

  • 达到PB-CR患者的中位校正OS为22.8个月(95%CI 18.9-26.2),未达到者为10.4个月(95%CI 9.7-11.2),HR=0.366(95%CI 0.303-0.441;p<.0001)。
  • 在达到形态学CR的患者中,额外达到PB-CR者的中位校正OS为32.6个月(95%CI 26.2-49.2),未达到者为21.7个月(95%CI 16.9-27.7;HR=0.400,95%CI 0.190-0.844;p=.0161)。

关键数值与推荐

  • PB-CR定义为可由白细胞分类计数和临床参数判定、无需骨髓评估的缓解类型。

临床怎么用

  • 作者认为,仅以识别CR/CRi为目的的骨髓评估可以省略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with incomplete count recovery (CRi), both of which require an invasive BM evaluation. Outside of clinical trials, BM evaluations are only performed in ~50% of patients during follow-up, pinpointing a clinical need for response endpoints that do not necessitate BM assessments. We define and validate a new response type termed "peripheral blood complete remission" (PB-CR) that can be determined from the differential blood count and clinical parameters without necessitating a BM assessment. We compared the predictive value of PB-CR with morphologic CR/CRi in 1441 non-selected, consecutive patients diagnosed with MDS (n = 522; 36.2%), CMML (n = 132; 9.2%), or AML (n = 787; 54.6%), included within the Austrian Myeloid Registry (aMYELOIDr; NCT04438889). Time-to-event analyses were adjusted for 17 covariates remaining in the final Cox proportional hazards (CPH) model. DeepSurv, a CPH neural network model, and permutation-based feature importance were used to validate results. 1441 patients were included. Adjusted median overall survival for patients achieving PB-CR was 22.8 months (95%CI 18.9-26.2) versus 10.4 months (95%CI 9.7-11.2) for those who did not; HR = 0.366 (95%CI 0.303-0.441; p < .0001). Among patients achieving CR, those additionally achieving PB-CR had a median adjusted OS of 32.6 months (95%CI 26.2-49.2) versus 21.7 months (95%CI 16.9-27.7; HR = 0.400 [95%CI 0.190-0.844; p = .0161]) for those who did not. Our deep neural network analysis-based findings from a large, prospective cohort study indicate that BM evaluations solely for the purpose of identifying CR/CRi can be omitted.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pleyer L, Vaisband M, Drost M, et al. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT. Am J Hematol. 2023. PMID: 37548390. doi:10.1002/ajh.27046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。